Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progress in genitourinary cancer.

G P Murphy, D J Fink

    Cancer
    |August 1, 1987
    PubMed
    Summary
    This summary is machine-generated.

    Advances in urologic cancer therapies have significantly improved patient survival rates. National surveys show substantial survival gains for testicular and prostate cancers, highlighting progress in treatment effectiveness.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Rotational Energy as Mass in H_{3}^{+} and Lower Limits on the Atomic Masses of D and ^{3}He.

    Physical review letters·2018
    Same author

    Activation of TLR-4 to produce tumour necrosis factor-α in neuropathic pain caused by paclitaxel.

    European journal of pain (London, England)·2014
    Same author

    Prolonged regulatable expression of EPO from an HSV vector using the LAP2 promoter element.

    Gene therapy·2011
    Same author

    Vector-mediated expression of erythropoietin improves functional outcome after cervical spinal cord contusion injury.

    Gene therapy·2011
    Same author

    Transgene-mediated expression of tumor necrosis factor soluble receptor attenuates morphine tolerance in rats.

    Gene therapy·2011
    Same author

    Analysis of HSV-DNA and RNA Using the Polymerase Chain Reaction.

    Methods in molecular medicine·2011
    Same journal

    Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor Study.

    Cancer·2026
    Same journal

    Large-scale osteosarcoma sequencing reveals age-associated genomic architectures.

    Cancer·2026
    Same journal

    EZH2 inhibitor tazemetostat voluntarily withdrawn from market.

    Cancer·2026
    Same journal

    Nivolumab and chemotherapy combination approved for previously untreated Hodgkin lymphoma.

    Cancer·2026
    Same journal

    Most older patients with advanced cancer prioritize QOL over extending survival: A secondary analysis of the GAP70+ trial found that among adults aged 70 and older with advanced, noncurable cancer, nearly three-quarters prioritized maintaining QOL.

    Cancer·2026
    Same journal

    Real-world safety, prognostic, and design considerations in ketogenic diet trials for pancreatic cancer.

    Cancer·2026
    See all related articles

    Area of Science:

    • Urology
    • Oncology
    • Cancer Research

    Background:

    • Significant advancements in urologic cancer therapies have led to improved patient survival.
    • There is a concern that cutting-edge research findings from academic centers may not be rapidly disseminated to community practices.

    Purpose of the Study:

    • To assess the dissemination and impact of new findings in urologic cancer treatment across the United States.
    • To evaluate the improvement in survival rates for specific urologic cancers over time.

    Main Methods:

    • National surveys were conducted by the American College of Surgeons across all 50 states, the District of Columbia, and Puerto Rico.
    • Analysis focused on survival data for nonseminomatous testicular cancer and localized/regionalized prostate cancer.

    Related Experiment Videos

    Main Results:

    • Between 1970 and 1983, the 2-year survival for nonseminomatous testicular cancer increased from 74% to 92%.
    • From 1974 to 1984, localized and regionalized prostate cancer survival rates saw improvements, with some exceeding a 10% increase in 5-year survival.

    Conclusions:

    • The data demonstrate substantial improvements in survival for key urologic cancers, reflecting successful treatment advancements.
    • Continued optimism for further progress in urologic oncology is warranted based on current trends and ongoing research.